Clear Search sequence regions


  • catalogue (2)
  • disease and (1)
  • humans (1)
  • interview (2)
  • patients (4)
  • skin colour (3)
  • social (4)
  • stigma (6)
  • Sizes of these terms reflect their relevance to your search.

    Cutaneous hyperpigmentation is one of the main adverse effects encountered in patients undergoing leprosy treatment with multidrug therapy (WHO-MDT). This adverse effect has been described as intolerable and capable of contributing to social stigma. The objectives of this study were to quantify the variation in skin colour induced by clofazimine during and after treatment and to assess the related stigma. This observational cross-sectional study objectively measured skin colour in 51 patients by reading the individual typology angle (ITA°) with a spectrophotometer, followed by the application of the Stigma Scale of the Explanatory Model Interview Catalogue (EMIC). Skin hyperpigmentation was observed in 100% of the individuals. They showed more negative ITA° values in lesion areas than non-lesion areas, particularly in sun-exposed regions. Clofazimine-induced cutaneous hyperpigmentation was not homogeneous and seemed to follow the lesion locations. The mean EMIC score was 18.8 points. All patients presented skin hyperpigmentation caused by clofazimine, detectable through spectrophotometry. Hyperpigmentation strongly impacted the social domain, indicating the intersectionality of disease and skin colour stigma, contributing to the social isolation of these patients. Health authorities should consider the negative impact of clofazimine on treatment adherence. © 2024 John Wiley & Sons Ltd.

    Citation

    Andreza Soares Nogueira, Monique Allana Chagas Garcia, Moises Batista da Silva, Patricia Fagundes da Costa, Marco Andrey Cipriani Frade, Claudio Guedes Salgado, Josafá Gonçalves Barreto. Clofazimine-induced cutaneous hyperpigmentation as a source of stigma in the treatment of leprosy: A cross-sectional study. Tropical medicine & international health : TM & IH. 2024 Apr;29(4):327-333

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 38348585

    View Full Text